Phase II Open Label Study to Evaluate the Safety of a Second I.P. Infusion Cycle of Catumaxomab in Patients With Malignant Ascites Due to Carcinoma, Requiring Their First Therapeutic Puncture After Treatment in the CASIMAS Study [EXTENSION OF 700040668]

Trial Profile

Phase II Open Label Study to Evaluate the Safety of a Second I.P. Infusion Cycle of Catumaxomab in Patients With Malignant Ascites Due to Carcinoma, Requiring Their First Therapeutic Puncture After Treatment in the CASIMAS Study [EXTENSION OF 700040668]

Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2014

At a glance

  • Drugs Catumaxomab (Primary)
  • Indications Malignant ascites
  • Focus Adverse reactions
  • Acronyms SECIMAS
  • Sponsors Neovii Biotech
  • Most Recent Events

    • 22 Mar 2014 A phase II study (SECIMAS) in patients receiving a second treatment cycle from the CASIMA patient population is going to occur, according to information presented at ASCO 2010.
    • 22 Mar 2014 According to ClinicalTrials.gov record, up to 30 evaluable patients from the CASIMAS study were expected to be enrolled.
    • 21 Mar 2014 New source identified and integrated (European Clinical Trial register, EudraCT2009-014076-22)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top